搜索结果
靶点ID:TCMBANKGE003699
靶点别名:ADF; AGEL
靶点描述:gelsolin
染色体:9
染色体位置:9q33.2
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:4620
OMIM_Link:137350
Ensembl_Link:ENSG00000148180
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000077 | sulfur dioxide | Sulfurous acid anhydride; Sulfur superoxide; FEMA 3039; FEMA No. 3039; Sulfur dioxide [NF]; Sulfur dioxide (SO2); 8014-94-6; CHEMBL1235997; CTK2H7729; Sulfur dioxide (NF); Caswell No. 813; [SO2]; D05961; Sulfur dioxide,liquid; Schwefeldioxyd; Schwefeldioxid; Sulfur dioxide [UN1079] [Poison gas]; Fermenicide liquid; SO2; 115004-27-8; sulphur dioxide; Sulfurous oxide; CHEBI:18422; Sulfur dioxide (SO2) 10% by volume or more SO2; AKOS015904447; SC-81833; 12396-99-5; Sulfurous anhydride; Sulfur dioxide, >=99.9%; R-764; Oxosulfane oxide #; I14-17276; HSDB 228; Fermenticide liquid; Surfur dioxide (anhydrous); sulfer dioxide; RAHZWNYVWXNFOC-UHFFFAOYSA-; Sulfur dioxide, puriss., >=99.9%; Oxosulfane oxide; EPA Pesticide Chemical Code 077601; E220; ACMC-1BHHQ; Sulfur oxide (SO2); DTXSID6029672; LS-3224; Siarki dwutlenek; Sulfur dioxide [UN1079] [Poison gas]; Fermenicide powder; Schwefeldioxyd [German]; 7446/9/5; C09306; CCRIS 9001; Sulfur(IV) oxide; dioxidosulfur; Sulfur dioxide, >=99.98%; 1239882-82-6; AC1L1ARN; TR-024070; UN1079; Siarki dwutlenek [Polish]; InChI=1/O2S/c1-3-2; SULFUR-DIOXIDE; Dioxide, Sulfur; Schwefel(IV)-oxid; UN 1079; 0UZA3422Q4; RAHZWNYVWXNFOC-UHFFFAOYSA-N; EC 231-195-2; 83008-56-4; EINECS 231-195-2; Sulfurdioxide; 89125-89-3; UNII-0UZA3422Q4; Anhydride, Sulfurous | SO2 | 64.07 g/mol | O=S=O |
| TCMBANKIN004686 | realgar | AsHS | 0 | S[As] | |
| TCMBANKIN057324 | Sulfur dioxide;sulfur dioxide | Sulfurous acid anhydride; Sulfur superoxide; FEMA 3039; FEMA No. 3039; Sulfur dioxide [NF]; Sulfur dioxide (SO2); 8014-94-6; CHEMBL1235997; CTK2H7729; Sulfur dioxide (NF); Caswell No. 813; [SO2]; D05961; Sulfur dioxide,liquid; Schwefeldioxyd; Schwefeldioxid; Sulfur dioxide [UN1079] [Poison gas]; Fermenicide liquid; SO2; 115004-27-8; sulphur dioxide; Sulfurous oxide; CHEBI:18422; Sulfur dioxide (SO2) 10% by volume or more SO2; AKOS015904447; SC-81833; 12396-99-5; Sulfurous anhydride; Sulfur dioxide, >=99.9%; R-764; Oxosulfane oxide #; I14-17276; HSDB 228; Fermenticide liquid; Surfur dioxide (anhydrous); sulfer dioxide; RAHZWNYVWXNFOC-UHFFFAOYSA-; Sulfur dioxide, puriss., >=99.9%; Oxosulfane oxide; EPA Pesticide Chemical Code 077601; E220; ACMC-1BHHQ; Sulfur oxide (SO2); DTXSID6029672; LS-3224; Siarki dwutlenek; Sulfur dioxide [UN1079] [Poison gas]; Fermenicide powder; Schwefeldioxyd [German]; 7446/9/5; C09306; CCRIS 9001; Sulfur(IV) oxide; dioxidosulfur; Sulfur dioxide, >=99.98%; 1239882-82-6; AC1L1ARN; TR-024070; UN1079; Siarki dwutlenek [Polish]; InChI=1/O2S/c1-3-2; SULFUR-DIOXIDE; Dioxide, Sulfur; Schwefel(IV)-oxid; UN 1079; 0UZA3422Q4; RAHZWNYVWXNFOC-UHFFFAOYSA-N; EC 231-195-2; 83008-56-4; EINECS 231-195-2; Sulfurdioxide; 89125-89-3; UNII-0UZA3422Q4; Anhydride, Sulfurous | O2S;SO2 | 64.0638 | O=S=O |
| TCMBANKIN057906 | mercury | hydrargyrum | Hg | 200.59 g/mol | [Hg] |
| TCMBANKIN057911 | se | selenium | H2Se | 78.97 g/mol | [Se] |
| TCMBANKIN059684 | Vitamin E β- | C29H50O2 | 430.79 | CC1=C(C(=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)C)O | |
| TCMBANKIN059746 | α-tocopherol | C29H50O2 | 430.7 g/mol | CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C | |
| TCMBANKIN061671 | dl-tetrahydropalmatine | dl-tetrahydropalmatine;AIDS002241; 84-38-8; 13a-alpha-Berbine, 2,3,9,10-tetramethoxy-; CHEBI:16563; 6H-Dibenzo(a,g)quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, (S)-; (S)-5,8,13,13a-Tetrahydro-2,3,9,10-tetramethoxy-6H-dibenzo(a,g)quinolizine; AIDS-002241; C02890; Hyndarine; (-)-Corydalis; 4880-82-4 (HCL); NSC36363 (HCL); InChI=1/C21H25NO4/c1-23-18-6-5-13-9-17-15-11-20(25-3)19(24-2)10-14(15)7-8-22(17)12-16(13)21(18)26-4/h5-6,10-11,17H,7-9,12H2,1-4H3/t17-/m0/s; 5,8,13,13a-Tetrahydro-2,3,9,10-tetramethoxy-6H-dibenzo(a,g)quinolizine; 5,8,13,13a(S)-Tetrahydro-2,3,9,10-tetramethoxy-6H-dibenzo[a,g]quinolizine; 2-(2,3-Dimethoxy-benzyl)-1-ethyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline; BB_NC-1018; Gindarine; Tetrahydropalmatine (6CI); Berbine, 2,3,9,10-tetramethoxy- (8CI); Tetrahydropalmatine; l-Tetrahydropalmatine; (S)-Tetrahydropalmatine; Caseanine; 6H-Dibenzo(a,g)quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-; Rotundine; (13aS)-2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline; 483-14-7; (13aS)-2,3,9,10-tetramethoxy-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinoline; 6H-dibenzo[a,g]quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, (13aS)-; (-)-Tetrahydropalmatine;2,3,9,10-Tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinoline hydrochloride; 2,3,9,10-Tetramethoxy-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinoline hydrochloride; AKOS024399264; MolPort-002-321-247; Berbine,3,9,10-tetramethoxy-, hydrochloride; NSC-132057; NSC-209411; 2,3,9,10-Tetramethoxyberbine hydrochloride; 6024-85-7; CHEMBL1412574; NSC132058; Palmatine, hydrochloride, (.+-.)-; 6H-Dibenzo[a, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, hydrochloride, (R)-; Tetrahydropalmatine hydrochloride; 024T857; C-55689; MCULE-7006385138; Palmatine, hydrochloride, (+)-; A832652; 6H-Dibenzo[a, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, hydrochloride; MLS000029596; Ambotz6024-85-7; 2506-20-9; FT-0698667; 6H-Dibenzo[a, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, hydrochloride, (.+-.)-; WLN: T D6 B666 KN&TT&J GO1 HO1 PO1 QO1 &GH; AC1O7ERI; NSC132057; NSC-132058; MLS002535962; AK310574; 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline hydrochloride; AC-8031; 13a.beta.-Berbine,3,9,10-tetramethoxy-, hydrochloride; Berbine,3,9,10-tetramethoxy-, hydrochloride, (+)-; NSC209411; Berbine,3,9,10-tetramethoxy-, hydrochloride, (.+-.)-; 3,4,10,11-tetramethoxy-7,8,12b,13-tetrahydro-5H-6000000-azatetraphene hydrochloride; SCHEMBL3502167; AC1Q3C4E; D-Tetrahydropalmatine hydrochloride; Tetrahydropalmatine, HCl; SMR000008833;(13aR)-2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline;Hyndarin;tetrahydropalmatine;L-tetrahydropalmatine;STOCK1N-14407 | C21H25NO4 | 355.4 g/mol | COC1=C(C2=C(CC3C4=CC(=C(C=C4CCN3C2)OC)OC)C=C1)OC |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000009 | Neoplasms | Abnormality of the nervous system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI000018 | Digestive System Diseases; Neoplasms; Endocrine System Diseases | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI000023 | Skin and Connective Tissue Diseases; Immune System Diseases | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI000035 | Digestive System Diseases; Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI000061 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | group | |
| TCMBANKDI000076 | Neoplasms | - | Neoplastic Process | group | |
| TCMBANKDI000088 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | group | |
| TCMBANKDI000167 | Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI000294 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI000802 | Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases | Abnormality of the integument | Finding | phenotype | |
| TCMBANKDI002512 | Digestive System Diseases | Abnormality of the digestive system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI003411 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI004208 | Neoplasms | Neoplasm; Abnormality of the breast | Neoplastic Process | disease | |
| TCMBANKDI005092 | Neoplasms; Nutritional and Metabolic Diseases; Immune System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI005318 | Digestive System Diseases; Chemically-Induced Disorders | - | Disease or Syndrome | disease | |
| TCMBANKDI007520 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
| TCMBANKDI007737 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI008166 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI008407 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases | Abnormality of the integument | Disease or Syndrome | disease | |
| TCMBANKDI009231 | Pathological Conditions, Signs and Symptoms; Infections | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI009702 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | phenotype | |
| TCMBANKDI009722 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | - | Pathologic Function | phenotype | |
| TCMBANKDI010160 | Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | group | |
| TCMBANKDI010239 | Chemically-Induced Disorders; Mental Disorders | - | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI011173 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI011174 | Infections | - | Disease or Syndrome | group | |
| TCMBANKDI011557 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI011597 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Eye Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI011743 | Neoplasms; Skin and Connective Tissue Diseases | Neoplasm; Abnormality of the breast | Neoplastic Process | group | |
| TCMBANKDI012916 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI012932 | Infections; Immune System Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI013453 | Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of metabolism/homeostasis; Abnormality of the genitourinary system | Finding | phenotype | |
| TCMBANKDI013628 | Neoplasms; Skin and Connective Tissue Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI015044 | Pathological Conditions, Signs and Symptoms; Eye Diseases; Nervous System Diseases; Mental Disorders; Otorhinolaryngologic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI015485 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI015757 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI016890 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017642 | Neoplasms | Abnormality of the integument; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI017869 | Nervous System Diseases | Abnormality of the nervous system; Abnormality of the musculature | Disease or Syndrome | disease | |
| TCMBANKDI018854 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI019302 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases | Abnormality of the digestive system | Anatomical Abnormality | disease | |
| TCMBANKDI019825 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI019962 | Infections; Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | group | |
| TCMBANKDI020243 | - | - | Neoplastic Process | disease | |
| TCMBANKDI020574 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Stomatognathic Diseases | Abnormality of the nervous system; Abnormality of head or neck; Abnormality of the musculature | Disease or Syndrome | disease | |
| TCMBANKDI022473 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI024262 | - | - | Neoplastic Process | phenotype | |
| TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI024935 | Endocrine System Diseases | Abnormality of the endocrine system | Disease or Syndrome | phenotype | |
| TCMBANKDI025313 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI026158 | Musculoskeletal Diseases; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI026233 | - | Abnormality of the integument | Anatomical Abnormality | disease | |
| TCMBANKDI026963 | Pathological Conditions, Signs and Symptoms | - | Acquired Abnormality | disease | |
| TCMBANKDI027235 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Nervous System Diseases | Abnormality of the eye | Disease or Syndrome | disease | |
| TCMBANKDI027682 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI027903 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI028561 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI029289 | Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases | Abnormality of the integument | Disease or Syndrome | disease | |
| TCMBANKDI029321 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI030540 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI031189 | Neoplasms | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI031417 | Skin and Connective Tissue Diseases | Abnormality of the integument | Sign or Symptom | phenotype | |
| TCMBANKDI032193 | Behavior and Behavior Mechanisms | Abnormality of the nervous system | Mental or Behavioral Dysfunction | phenotype | |
| TCMBANKDI032498 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease |
滇IICP备16009434号-1 |
Dai SX Lab